论文部分内容阅读
目的 :评价尿吡啶酚和脱氧吡啶酚对恶性肿瘤骨转移患者的临床意义。方法 :采用ELISA方法检测了2 6例限局性恶性肿瘤、35例进展期肿瘤骨转移阴性和 34例骨转移阳性的尿吡啶酚和脱氧吡啶酚水平。结果 :进展期肿瘤尿吡啶酚和脱氧吡啶酚水平明显高于限局性肿瘤 (P <0 .0 5 ) ;进展期肿瘤骨转移阳性尿吡啶酚和脱氧吡啶酚水平又明显高于骨转移阴性 (P <0 .0 5 )。结论 :尿吡啶酚和脱氧吡啶酚可以在评价进展期肿瘤骨转移和骨吸收中发挥作用。
Objective: To evaluate the clinical significance of uridine and deoxypyridinoline in patients with malignant bone metastases. METHODS: The levels of uridine and deoxypyridinoline were determined by ELISA in 26 localized malignant tumors, 35 bone metastases in advanced tumors, and 34 bone metastases. Results: The levels of uridine and deoxypyridinoline in the advanced stage tumors were significantly higher than those in the localized tumors (P < 0.05). The positive levels of uridine and deoxypyridinoline in advanced tumors were significantly higher than those in bone metastases (P <0.05). P <0. 0 5 ). Conclusion : Urine pyridinoline and deoxypyridinoline can play a role in the evaluation of bone metastases and bone resorption in advanced tumors.